Affiliated with a Castle Connolly Top Hospital
Who is Dr. Skinner, Urologist in Stanford, CA?
Dr. Eila Skinner, MD is an Urologist, who primarily practices in Stanford, CA with 2 additional practice locations. She is board certified. Dr. Skinner graduated from Keck School of Medicine of the University of Southern California and completed her residency at USC/LAC Medical Center. Dr. Skinner is fluent in English and Spanish, and is currently seeing new patients. Dr. Skinner’s practice accepts Kaiser Permanente, Medicaid, Medicare, Aetna, Cigna, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Skinner’s office at (312) 416-9997.
What are Areas of Expertise for Dr. Skinner?
Dr. Eila Skinner, MD is a highly-rated, board-certified Urologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Skinner empowers patients to confidently navigate their health journey, specializing in Bladder Cancer, Bladder Reconstruction, Continent Urinary Diversions, Urologic Cancer, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Skinner is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Skinner go to medical school and complete their residency?
Fellowship: USC Norris Comprehensive Cancer Center
Residency: USC/LAC Medical Center | USC/LAC-Keck School of Medicine
Medical School: Keck School of Medicine of the University of Southern California
Is Dr. Skinner board certified as an Urologist?
Yes, Dr. Eila Skinner, MD is board certified by the American Board of Urology , American Board of Urology since 1992
What languages does Dr. Skinner speak?
Dr. Skinner and their clinical team can communicate with patients in the following languages:
English
Spanish
What conditions does an Urologist like Dr. Skinner typically treat?
As an Urologist, Dr. Skinner diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Skinner. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Personal History of Bladder Cancer
- Bladder Cancer
- Past bladder cancer
- Previous urinary bladder malignancy
- History of bladder tumor
ICD-10 Codes:
- Z8551: Personal history of malignant neoplasm of bladder
Also known as:
- Bladder Cancer
- Urinary Bladder Cancer
- Bladder Carcinoma
ICD-10 Codes:
- C679: Malignant neoplasm of bladder, unspecified
- C672: Malignant neoplasm of lateral wall of bladder
- C674: Malignant neoplasm of posterior wall of bladder
Also known as:
- Cancer Follow-up Exam
- Cancer
- Post-cancer treatment checkup
- Malignancy surveillance
- Oncology follow-up
ICD-10 Codes:
- Z08: Encounter for follow-up examination after completed treatment for malignant neoplasm
Also known as:
- Prostate Cancer
- Prostate Cancer Treatment (PDQ®)
- Prostatic Carcinoma
- Prostate Gland Cancer
- Malignant Prostate Tumor
ICD-10 Codes:
- C61: Malignant neoplasm of prostate
Also known as:
- Bladder Cancer
- Urinary Bladder Cancer
- Bladder Tumor
- Urothelial Carcinoma of Bladder
ICD-10 Codes:
- C678: Malignant neoplasm of overlapping sites of bladder
What procedures does an Urologist like Dr. Skinner typically perform?
As an Urologist, Dr. Skinner performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Skinner. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Bladder and Urethra Scope
- Cystoscopy
- Urethroscopy
- Bladder scope procedure
CPT Codes:
- 52000: Cystourethroscopy (separate procedure)
Also known as:
- Bladder Cancer Medicine Instillation
- Intravesical Chemotherapy
- Bladder Drug Instillation
- Anticancer Bladder Treatment
CPT Codes:
- 51720: Bladder instillation of anticarcinogenic agent (including retention time)
Also known as:
- Bladder Tumor Removal (Medium Size)
- Small Bladder Tumor Removal (Cystoscopy)
- Bladder Tumor Removal (Large Size)
- Cystoscopy with Bladder Tumor Resection
- Bladder Tumor Fulguration
- Laser Removal of Bladder Tumor
- Cystourethroscopy with Bladder Tumor Resection
- Cystoscopy with Large Bladder Tumor Resection
- Large Bladder Tumor Fulguration
- Laser Removal of Large Bladder Tumor
CPT Codes:
- 52235: Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; MEDIUM bladder tumor(s) (2.0 to 5.0 cm)
- 52234: Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; SMALL bladder tumor(s) (0.5 up to 2.0 cm)
- 52240: Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; LARGE bladder tumor(s)
Also known as:
- Temporary Bladder Catheter Insertion
- Straight Catheterization
- Intermittent Catheterization
- Urine Retention Catheter
CPT Codes:
- 51701: Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)
Also known as:
- Bladder and Urethra Scope with Biopsy
- Cystoscopy with Biopsy
- Urethroscopy with Biopsy
- Bladder Biopsy
CPT Codes:
- 52204: Cystourethroscopy, with biopsy(s)
Also known as:
- Bladder Scope with Removal of Foreign Body or Stent
- Cystourethroscopy for Foreign Body
- Bladder Stone Removal with Scope
- Ureteral Stent Removal (Cystoscopic)
CPT Codes:
- 52310: Cystourethroscopy, with removal of foreign body, calculus, or ureteral stent from urethra or bladder (separate procedure); simple
Does Dr. Skinner accept my insurance?
Dr. Skinner accepts most major insurance plans. Important: Please call our office at (312) 416-9997 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Skinner accept in Stanford, CA?
Dr. Skinner in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
AllCare Health
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Federal government of the United States
Medicaid
Medicare
Santa Cruz County
State of California
UnitedHealth Group
View All Insurances
Where is Dr. Skinner's office located?
What hospitals are Dr. Skinner affiliated with?
Castle Connolly Top Hospital
This doctor is affiliated with a Castle Connolly Top Hospital.
Dr. Skinner has admitting privileges at the following hospitals:
Recognitions
Publications
Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node
, 2014
Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinbl
, 2013
Uriry Functiol Outcome Following Radical Cystoprostatectomy
, 2013
Combition of Molecular Alterations
, 2013
ICUD-EAU Intertiol Consultation on Bladder Cancer 2012: Uriry Diversion
, 2013
Radical cystectomy with orthotopic neobladder reconstruction following prior radical prostatectomy
, 2012
Super Extended Versus Extended Pelvic Lymph Node Dissection
, 2011
Choosing the right uriry diversion: Patient's choice or surgeon's inclition?
, 2011
Disease-Free Survival at 2 or 3 Years Correlates With 5
, 2011
Early Complications of Cystectomy After High Dose Pelvic Radiation
, 2010
Soft Tissue Surgical Margin Status is a Powerful Predictor of Outcomes After Radical Cystectomy
, 2010
Intertiol validation of the prognostic value of lymphovascular invasion
, 2010
Does reflux in orthotopic diversion matter? A randomized prospective comparison of the Studer and T
, 2009
Guideline for the magement of nonmuscle invasive bladder cancer (Stages Ta, T1
, 2007
Radical cystectomy with extended lymphadenectomy
, 2007
Surgical benchmarks for the treatment of invasive bladder cancer
, 2007
Quality of life after cystectomy and uriry diversion: An evidence based alysis
, 2005
Prognostic significance of lymphovascular invasion of bladder cancer treated with radical
, 2005
Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy
, 2004
Prognosis of semil vesicle involvement by transitiol cell carcinoma of the bladder
, 2004
High-risk localized prostate cancer: primary surgery and adjuvant therapy
, 2003
Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients
, 2001
Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit
, 1999
Hydronephrosis as a prognostic indicator in bladder cancer patients
, 1998
The effect of fisteride on the prostate gl
, 1998
25-year experience in the magement of invasive bladder cancer by radical cystectomy
, 1998
Orthotopic lower uriry tract reconstruction in women using the kock ileal neobladder
, 1997
Transitiol cell carcinoma involving the prostate with a proposed staging cl
, 1996
Magement of complex urologic injuries
, 1996
Complications of the afferent antireflux valve mechanism in the kock ileal reservoir
, 1996
Alterations in circulating levels of androgens and PSA during treatment with fisteride in men at
, 1996
INDICATIONS FOR LOWER URIRY-TRACT RECONSTRUCTION IN WOMEN AFTER CYSTECTOMY FOR BLADDER
, 1995
DOES THE RACIAL-ETHNIC VARIATION IN PROSTATE-CANCER RISK HAVE A HORMOL BASIS
, 1995
Uriry functiol outcomes in female neobladder patients.
, 2014
Radical cystectomy and orthotopic uriry diversion in male patients with pT4a urothelial bladder
, 2013
Incidental Prostate Cancer in Patients with Bladder Urothelial Carcinoma
, 2013
Null Association Between Histology of First
, 2013
A novel precision-engineered microfiltration device for capture
, 2013
Ultered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades
, 2013
Critical alysis and validation of lymph node density as prognostic variable in urothelial carcinoma
, 2013
Long-term outcomes of salvage radical cystectomy for recurrent urothelial carcinoma of the bladder
, 2013
A precystectomy decision model to predict pathological upstaging
, 2013
Reproductive Organ Involvement in Female Patients Undergoing Radical Cystectomy
, 2012
Multicenter validation of the prognostic value of patient age
, 2012
Factors influencing post-recurrence survival in bladder cancer following radical cystectomy
, 2012
Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy
, 2011
Prognostic Risk Stratification of Pathological Stage T3N0 Bladder Cancer After Radical Cystectomy
, 2011
Discrepancy between clinical and pathological stage
, 2011
Concomitant Carcinoma in situ in Cystectomy Specimens Is Not Associated with Clinical Outcomes
, 2011
Stage pT0 at Radical Cystectomy Confers Improved Survival: An Intertiol Study of 4,430 Patients
, 2010
pT3 Substaging is a Prognostic Indicator
, 2010
Characteristics and Outcomes of Patients With Clinical Carcinoma In Situ Only Treated With Radical
, 2010
The best treatment for high-grade T1 bladder cancer is cystectomy
, 2007
Functiol heterogeneity of prostatic intraepithelial neoplasia
, 2007
A critical alysis of perioperative mortality from radical cystectomy
, 2006
Pubovagil slings for stress uriry incontinence following radical cystectomy
, 2004
Prevention of prostate cancer with fisteride.
, 2003
Quality of life with reconstruction.
, 2001
Continent and orthotopic uriry diversion following radical cystectomy. Should these reconstructive
, 1995
THE RATIOLE FOR EN-BLOC PELVIC LYMPH
, 1993
RADICAL CYSTECTOMY IN REGIOLLY ADVANCED BLADDER-CANCER
, 1992
URIRY-DIVERSION
, 1987
Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node
, 2014
Long-term cancer control after radical prostatectomy
, 2014
Impact of micropapillary urothelial carcinoma variant histology on survival after radical
, 2014
Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder
, 2014
Incidence and location of lymph node metastases in patients undergoing radical cystectomy for
, 2014
Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinbl
, 2013
Urinary Functional Outcome Following Radical Cystoprostatectomy
, 2013
Combination of Molecular Alterations
, 2013
ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary Diversion
, 2013
Radical cystectomy with orthotopic neobladder reconstruction following prior radical prostatectomy
, 2012
Critical Evaluation of the American Joint Committee on Cancer TNM Nodal Staging System
, 2012
Robotic and Laparoscopic High Extended Pelvic Lymph Node Dissection During Radical Cystectomy
, 2012
Super Extended Versus Extended Pelvic Lymph Node Dissection
, 2011
Choosing the right urinary diversion: Patient's choice or surgeon's inclination?
, 2011
Disease-Free Survival at 2 or 3 Years Correlates With 5
, 2011
Lymph node dissection technique is more important than lymph node count
, 2011
Early Complications of Cystectomy After High Dose Pelvic Radiation
, 2010
Soft Tissue Surgical Margin Status is a Powerful Predictor of Outcomes After Radical Cystectomy
, 2010
International validation of the prognostic value of lymphovascular invasion
, 2010
Does reflux in orthotopic diversion matter? A randomized prospective comparison of the Studer and T
, 2009
Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1
, 2007
Radical cystectomy with extended lymphadenectomy
, 2007
Surgical benchmarks for the treatment of invasive bladder cancer
, 2007
Quality of life after cystectomy and urinary diversion: An evidence based analysis
, 2005
Prognostic significance of lymphovascular invasion of bladder cancer treated with radical
, 2005
Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy
, 2004
Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder
, 2004
High-risk localized prostate cancer: primary surgery and adjuvant therapy
, 2003
Sexuality and intimacy following radical prostatectomy: Patient and partner perspectives
, 2002
Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients
, 2001
Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit
, 1999
Hydronephrosis as a prognostic indicator in bladder cancer patients
, 1998
The effect of finasteride on the prostate gl
, 1998
Radical cystectomy for elderly patients with bladder carcinoma
, 1998
25-year experience in the management of invasive bladder cancer by radical cystectomy
, 1998
Quality of life and sexuality following radical prostatectomy in patients with prostate cancer who
, 1997
Orthotopic lower urinary tract reconstruction in women using the kock ileal neobladder
, 1997
Transitional cell carcinoma involving the prostate with a proposed staging cl
, 1996
Management of complex urologic injuries
, 1996
Complications of the afferent antireflux valve mechanism in the kock ileal reservoir
, 1996
Alterations in circulating levels of androgens and PSA during treatment with fin
, 1996
INDICATIONS FOR LOWER URINARY-TRACT RECONSTRUCTION IN WOMEN AFTER CYSTECTOMY FOR BLADDER
, 1995
DOES THE RACIAL-ETHNIC VARIATION IN PROSTATE-CANCER RISK HAVE A HORMONAL BASIS
, 1995
Female gender is associated with a worse survival after radical cystectomy
, 2014
Urinary functional outcomes in female neobladder patients.
, 2014
Radical cystectomy and orthotopic urinary diversion in male patients with pT4a urothelial bladder
, 2013
Incidental Prostate Cancer in Patients with Bladder Urothelial Carcinoma
, 2013
Null Association Between Histology of First
, 2013
A novel precision-engineered microfiltration device for capture
, 2013
Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three
, 2013
Critical analysis and validation of lymph node density as prognostic variable in urothelial
, 2013
Long-term outcomes of salvage radical cystectomy for recurrent urothelial carcinoma of the bladder
, 2013
A precystectomy decision model to predict pathological upstaging
, 2013
Reproductive Organ Involvement in Female Patients Undergoing Radical Cystectomy
, 2012
Multicenter validation of the prognostic value of patient age
, 2012
Factors influencing post-recurrence survival in bladder cancer following radical cystectomy
, 2012
Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy
, 2011
Heterogenous effect of androgen receptor CAG tract length on testicular germ cell tumor risk
, 2011
Prognostic Risk Stratification of Pathological Stage T3N0 Bladder Cancer After Radical Cystectomy
, 2011
Discrepancy between clinical and pathological stage
, 2011
Concomitant Carcinoma in situ in Cystectomy Specimens Is Not Associated with Clinical Outcomes
, 2011
Stage pT0 at Radical Cystectomy Confers Improved Survival: An International Study of 4,430 Patients
, 2010
Extended lymphadenectomy in bladder cancer
, 2010
pT3 Substaging is a Prognostic Indicator
, 2010
Validation of the AJCC TNM Substaging of pT2 Bladder Cancer
, 2010
Characteristics and Outcomes of Patients With Clinical Carcinoma In Situ Only Treated With Radical
, 2010
Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with
, 2010
The best treatment for high-grade T1 bladder cancer is cystectomy
, 2007
Functional heterogeneity of prostatic intraepithelial neoplasia
, 2007
A critical analysis of perioperative mortality from radical cystectomy
, 2006
Pubovaginal slings for stress urinary incontinence following radical cystectomy
, 2004
Prevention of prostate cancer with finasteride.
, 2003
Quality of life with reconstruction.
, 2001
Continent and orthotopic urinary diversion following radical cystectomy. Should these
, 1995
XANTHOGRANULOMATOUS PYELONEPHRITIS - CLINICAL FINDINGS AND SURGICAL CONSIDERATIONS
, 1994
THE RATIONALE FOR EN-BLOC PELVIC LYMPH
, 1993
RADICAL CYSTECTOMY IN REGIONALLY ADVANCED BLADDER-CANCER
, 1992
RADICAL CYSTECTOMY
, 1991
URINARY-DIVERSION
, 1987
What is Dr. Skinner's NPI number?A National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Skinner's National Provider Identifier (NPI) number is 1588673941.
What common questions do patients ask about Dr. Skinner?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Skinner
What is Dr. Eila Skinner's specialty?
Dr. Skinner is an Urologist near Stanford, CA.
What does an Urologist do?
A urologist is a healthcare professional with specialization in managing both benign and malignant medical and surgical disorders of the genitourinary system and adrenal glands. They possess extensive knowledge and skills in endoscopic, percutaneous, and open surgical techniques for addressing congenital and acquired conditions of the urinary and reproductive systems, as well as their associated structures.
Is Dr. Eila Skinner affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Skinner is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see an Urologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see an Urologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Dr. Eila Skinner accepting new patients in Stanford, CA?
Yes, Dr. Eila Skinner is accepting new patients at this time.
Does Dr. Eila Skinner offer online booking?
Please contact Dr. Skinner's office at (312) 416-9997 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Dr. Eila Skinner?
Please contact Dr. Skinner's office at (312) 416-9997 to schedule an appointment.
Where is Dr. Skinner's office located?
Dr. Skinner's offices are located in Stanford, CA, Emeryville, CA, and Palo Alto, CA.
Which board certifications does Dr. Eila Skinner have?
Dr. Eila Skinner is certified by the American Board of Urology.
Other Urologist Near Stanford, CA
Urologist
Accepting patientsUrologist
Accepting patientsUrologist
Accepting patients